SG11201900163PA - Macrocycle kinase inhibitors - Google Patents

Macrocycle kinase inhibitors

Info

Publication number
SG11201900163PA
SG11201900163PA SG11201900163PA SG11201900163PA SG11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA
Authority
SG
Singapore
Prior art keywords
ste
international
san diego
center drive
california
Prior art date
Application number
SG11201900163PA
Inventor
Jingrong Jean Cui
Yishan Li
Evan W Rogers
Dayong Zhai
Jane Ung
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of SG11201900163PA publication Critical patent/SG11201900163PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI HIM 011101 0 01111011MM vu 1111110 HOED Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/022911 Al 01 February 2018 (01.02.2018) W I P0 I P C T (51) International Patent Classification: Declarations under Rule 4.17: A61K 31/519 (2006.01) C07D 498/02 (2006.01) CO7D 487/04 (2006.01) CO7D 498/12 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/US2017/044214 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 27 July 2017 (27.07.2017) — with international search report (Art. 21(3)) — (25) Filing Language: English before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) (30) Priority Data: 62/367,886 28 July 2016 (28.07.2016) US (71) Applicant: TP THERAPEUTICS, INC. [US/US]; 10628 Science Center Drive, Ste. 225, San Diego, California 92121 (US). (72) Inventors: CUI, Jingrong Jean; 10628 Science Center Drive, Ste. 225, San Diego, California 92121 (US). LI, Yis- han; 10628 Science Center Drive, Ste. 225, San Diego, Cal- ifornia 92121 (US). ROGERS, Evan W.; 10628 Science — Center Drive, Ste. 225, San Diego, California 92121 (US). = ZHAI, Dayong; 10628 Science Center Drive, Ste. 225, San Diego, California 92121 (US). UNG, Jane; 10628 Science = Center Drive, Ste. 225, San Diego, California 92121 (US). — = (74) Agent: LIPTAK, Vincent P.; BARNES & THORNBURG LLP, 11 South Meridian Street, Indianapolis, Indiana 46204 (US). Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, = = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, _ KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) = — kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — 1-1 1-1 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). cT ei ei © —.... 00 1-1 (54) Title: MACROCYCLE KINASE INHIBITORS 0 ei (57) : The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the 0 same, and methods of using the same to treat disease.
SG11201900163PA 2016-07-28 2017-07-27 Macrocycle kinase inhibitors SG11201900163PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367886P 2016-07-28 2016-07-28
PCT/US2017/044214 WO2018022911A1 (en) 2016-07-28 2017-07-27 Macrocycle kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201900163PA true SG11201900163PA (en) 2019-02-27

Family

ID=61016718

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900163PA SG11201900163PA (en) 2016-07-28 2017-07-27 Macrocycle kinase inhibitors

Country Status (15)

Country Link
US (1) US10689400B2 (en)
EP (1) EP3490564A4 (en)
JP (1) JP2019527230A (en)
KR (1) KR20190034225A (en)
CN (1) CN109715165A (en)
AU (1) AU2017302019A1 (en)
BR (1) BR112019001607A2 (en)
CA (1) CA3031100A1 (en)
IL (1) IL264395A (en)
MX (1) MX2019001125A (en)
RU (1) RU2019105587A (en)
SG (1) SG11201900163PA (en)
TW (1) TW201815799A (en)
WO (1) WO2018022911A1 (en)
ZA (1) ZA201901034B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193524A (en) 2014-01-24 2022-10-18 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
CA2989327A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
CA2992324A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
US11286264B2 (en) * 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN109516999B (en) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 Compounds useful as protein kinase modulators and uses thereof
DK3728271T3 (en) 2017-12-19 2022-12-19 Turning Point Therapeutics Inc Macrocyclic compounds for the treatment of diseases
US11555042B2 (en) 2018-03-28 2023-01-17 Fochon Biosciences, Ltd. Macrocyclic compounds as TRK kinases inhibitors
KR102545594B1 (en) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl Spray-dried dispersions and formulations of )-1H-pyrazole-4-carboxamide
JP2022505987A (en) 2018-10-22 2022-01-14 エスカー セラピューティクス，インコーポレイテッド TYK2 inhibitors and their use
US20220235070A1 (en) * 2019-05-21 2022-07-28 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
CN113773335A (en) * 2019-06-21 2021-12-10 成都海博为药业有限公司 Compound as protein kinase inhibitor and preparation method and application thereof
WO2021027503A1 (en) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 Tricyclic compound, preparation method therefor, and intermediate and use thereof
WO2021178296A1 (en) * 2020-03-02 2021-09-10 Turning Point Therapeutics, Inc. Therapeutic uses of macrocyclic compounds
CN113754682B (en) * 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 Compound having macrocyclic structure and use thereof
CN116829562A (en) * 2021-02-10 2023-09-29 深圳国顺康医药科技有限公司 Macrocyclic compound, pharmaceutical composition and application thereof
CN113354548A (en) * 2021-04-12 2021-09-07 常熟耐素生物材料科技有限公司 Plant polyene phenolic aldehyde amine epoxy curing agent based on hexamethylenetetramine and preparation method thereof
WO2023078267A1 (en) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 Amino-containing macrocyclic compound as protein kinase modulator
WO2023208244A1 (en) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 Macrocyclic compound and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263403A (en) 1993-03-25 1996-10-28 Upjohn Co (oxa)cycloalkyl fused indole and benzofuran amines
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2010028116A1 (en) 2008-09-08 2010-03-11 Merck Serono S.A. Macrocyclics pyrimidines as aurora kinase inhibitors
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
PT2350071E (en) 2008-10-22 2014-04-11 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
PE20131197A1 (en) 2008-10-31 2013-11-06 Genentech Inc PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
US8757434B2 (en) * 2010-07-01 2014-06-24 The Coca-Cola Company Merchandiser
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
BR112013029711B1 (en) * 2011-05-19 2020-05-12 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii COMPOUNDS
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003798A2 (en) 2011-08-19 2017-03-01 Merck Sharp & Dohme method for making a compound, and, compound
JP6046728B2 (en) 2011-09-30 2016-12-21 オンコデザイン エス．ア． Macrocyclic FLT3 kinase inhibitor
US9096609B2 (en) * 2011-09-30 2015-08-04 Ipsen Pharma S.A.S. Macrocyclic LRRK2 kinase inhibitors
MX350844B (en) 2012-03-06 2017-09-22 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases.
KR102085121B1 (en) 2012-03-09 2020-03-05 렉시컨 파마슈티컬스 인코퍼레이티드 Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
HUE038786T2 (en) 2012-03-09 2018-11-28 Lexicon Pharmaceuticals Inc PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2014140299A1 (en) * 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
CN104513253A (en) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 Macrocyclic compounds for the treatment of proliferative diseases
MY193524A (en) * 2014-01-24 2022-10-18 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
CA2989327A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
MX2017017081A (en) 2015-07-06 2018-08-16 Tp Therapeutics Inc Diaryl macrocycle polymorph.
CA2992324A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
TW201815799A (en) 2018-05-01
ZA201901034B (en) 2021-06-30
CN109715165A (en) 2019-05-03
RU2019105587A (en) 2020-08-28
IL264395A (en) 2019-02-28
RU2019105587A3 (en) 2020-11-18
WO2018022911A1 (en) 2018-02-01
JP2019527230A (en) 2019-09-26
KR20190034225A (en) 2019-04-01
BR112019001607A2 (en) 2019-04-30
AU2017302019A1 (en) 2019-02-07
EP3490564A1 (en) 2019-06-05
CA3031100A1 (en) 2018-02-01
MX2019001125A (en) 2019-06-12
EP3490564A4 (en) 2020-02-26
US10689400B2 (en) 2020-06-23
US20190169208A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201907023UA (en) Method of reducing neutropenia
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same